EYPT EyePoint Pharmaceuticals Inc.

1.28
-0.17  -12%
Previous Close 1.45
Open 1.4
Price To Book 4.92
Market Cap 138,390,323
Shares 108,117,440
Volume 921,167
Short Ratio
Av. Daily Volume 529,389
Stock charts supplied by TradingView

NewsSee all news

  1. EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress

    – U.S. commercial launch trajectory for DEXYCU® and YUTIQ® gains momentum with strong customer order growth over Q2 – – DEXYCU customer orders increased 207% over Q2 with repeat customers representing 74% of order

  2. EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule

    - DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees - WATERTOWN, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals,

  3. EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®

    WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

  4. EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information

    WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will

  5. EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect

    WATERTOWN, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Iluvien
Diabetic macular edema
FDA approval announced October 15, 2018.
YUTIQ
Non-infectious uveitis
sNDA filing due 2019 for 6-month formulation.
Yutiq
Non-infectious uveitis

Latest News

  1. EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress

    – U.S. commercial launch trajectory for DEXYCU® and YUTIQ® gains momentum with strong customer order growth over Q2 – – DEXYCU customer orders increased 207% over Q2 with repeat customers representing 74% of order

  2. EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule

    - DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees - WATERTOWN, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals,

  3. EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®

    WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

  4. EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information

    WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will

  5. EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect

    WATERTOWN, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products,

  6. EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

    WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

  7. EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    WATERTOWN, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

  8. EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting

    WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today